April 16, 2025 Nvidia’s $5.5B AI Chip Crunch and ASML’s Tariff Jitters
April 23, 2025 Oleksandr Orlovskyi: Reviews, Biography, and All About Cryptocurrency
March 12, 2025 Features of exchanging USDC ERC20 to Bank Transfer
February 19, 2025 Why Stock Caps Matter When Building a Diversified Portfolio
February 5, 2025 Top 5 Coins for the Maximum Passive Income from Staking by 2024
January 21, 2025 Trading Stocks With AI: A Modern Approach
ACADIA Pharmaceuticals (ACAD) Stock Forecast for 2025, 2026, 2027. Sell or Buy?
Updated: May 15, 2025 (21:43)
Sector: HealthcareThe share price of ACADIA Pharmaceuticals Inc. (ACAD) now
News Impact Analyzer
Full report
This Week
|
Bearish | Impact: 5 | News: 1 |
Previous Week
|
Bullish | Impact: 5 | News: 2 (2/0/0) |
Two Weeks Ago
|
Na | Impact: Na | News: Na |
Three Weeks Ago
|
Na | Impact: Na | News: Na |
Analysts predictions
Full report
This Week
|
Bullish | Opinions: 1 (1/0/0) |
Previous Week
|
Neutral | Opinions: Na |
Two Weeks Ago
|
Neutral | Opinions: Na |
Three Weeks Ago
|
Neutral | Opinions: Na |
Analyzing the Most Important ACAD news

Acadia Pharmaceuticals: Major Stakeholder Sale of 43.6M Shares Filed


ACADIA Targets Robust Growth with $244M Revenue in Q1, Driven by DAYBUE and NUPLAZID Success


Acadia Pharma Surpasses Expectations with Strong Q1 Earnings and Revenue Growth

Historical and forecast chart of ACADIA Pharmaceuticals stock
The chart below shows the historical price of ACADIA Pharmaceuticals stock and a prediction chart for the next month.
For convenience, prices are divided by color. Forecast prices include: Optimistic Forecast, Pessimistic Forecast,
and Weighted Average Best Forecast. Detailed values for the ACADIA Pharmaceuticals stock price can be found in the table below.
Long-term forecasts by years.
ACADIA Pharmaceuticals Inc. Analysts predictions review

ACADIA Pharmaceuticals is poised for growth, driven by strategic pipeline diversification and expansion into underserved therapeutic areas. The focus on regulatory approvals for broader indications, combined with strong R&D alliances, enhances its revenue potential. Operational efficiencies and cost management further support margin expansion, mitigating risks from elevated R&D spending. Favorable regulatory tailwinds and growing institutional interest add to the stock's upside momentum, signaling robust investor confidence and potential for continued valuation increases.

ACADIA Pharmaceuticals: Catalysts Driving Growth and Strategic Expansion

ACADIA Pharmaceuticals is demonstrating significant progress across multiple operational fronts, signaling a promising outlook for its stock. The company’s expansion into new indications for existing drug assets represents a critical strategic initiative. By pursuing FDA approvals for broader applications, ACADIA aims to solidify its revenue base and mitigate reliance on a single product, potentially driving valuation higher in the near term. The author emphasizes the importance of precision in execution during this approval process as a key determinant of stock momentum.
Pipeline Diversification and Market Opportunities
ACADIA’s diversification of its drug pipeline reflects management’s focus on targeting underserved therapeutic areas, which could provide substantial market opportunities. Leveraging its successful track record in neurological conditions, the firm is expanding into adjacent fields, improving its competitive positioning. The author highlights that these developments reduce the risks associated with product-specific revenue streams, thus enhancing investor confidence.
Furthermore, the company’s strategic partnerships and acquisitions continue to strengthen its R&D capabilities and commercialization potential. These collaborative efforts position ACADIA to capitalize on innovation while benefiting from external expertise, adding a layer of operational synergy. If executed effectively, this approach can act as a growth multiplier, giving the stock an upward bias.

Acadia Pharmaceuticals Poised for Growth Amid Strategic Momentum and FY2024 Gains

Acadia Pharmaceuticals has demonstrated robust performance by leveraging its strong market position in the neuroscience space and delivering solid revenue growth. The company’s focus on expanding its product pipeline, notably in areas with significant unmet medical needs, reflects an aggressive strategy to sustain momentum and drive long-term shareholder value.
Pipeline Development and Strategic Positioning
One critical driver behind ACAD's outlook is its advanced-stage drug candidates and their potential upcoming approvals. The commercialization of these assets could be transformative in propelling earnings and enhancing market penetration, particularly in the mental health and central nervous system (CNS) segments.
The author emphasizes that cost management and operational efficiencies have also played a pivotal role in achieving profitability. This operational discipline bodes well for margin expansion, offsetting near-term risks associated with increased R&D expenditures as the company invests in its pipeline.

Acadia Pharmaceuticals: Strong Progress Signals a Strategic Shift to 'Buy'

A critical driver for Acadia Pharmaceuticals' improving outlook is its continued progress in expanding its key product portfolio. The company has demonstrated meaningful advancements in leveraging its existing pipeline, with particular emphasis on regulatory approvals that enhance its revenue growth potential. This expansion fortifies its market presence and is expected to act as a catalyst for top-line growth in the near-term.
Another factor underpinning the upgraded outlook is the management's ability to execute on operational efficiencies. Efforts to control costs without compromising innovation signify a sustainable pathway towards profitability. The impact of these measures is likely to strengthen investor confidence, which would further buoy the stock price.
Regulatory and Market Tailwinds Strengthen Near-Term Prospects
Additionally, a favorable regulatory environment and increased adoption for key treatments stand out as significant tailwinds. These developments not only minimize potential downside risks but also create an environment conducive to long-term growth. Market dynamics appear supportive, enhancing the probability of continued stock price appreciation.
Lastly, analysts, including the author, point to catalysts in the form of increased institutional investment. Investor sentiment has shifted markedly, signaling broader enthusiasm about the company’s growth trajectory. This trend may further accelerate demand for the stock, driving momentum in its valuation.
Acadia Pharmaceuticals' recent performance has been underpinned by encouraging developments in drug approvals and expansion efforts. The company’s flagship product, Nuplazid, has secured regulatory backing for expanded indications, demonstrating strong commercial potential and establishing a competitive moat in its target markets. These approvals, alongside management's proactive approach to broadening the product pipeline, are clear signals of sustainable revenue growth over the medium term.
Importantly, Acadia’s strategic focus on internal pipeline development shows impressive traction. Key late-stage clinical trials have yielded promising results, increasing the likelihood of bringing additional high-margin therapies to the market. This not only diversifies Acadia’s revenue base but also materially de-risks its business model from over-reliance on a single product.
The Role of Strategic Partnerships and Market Positioning
The company’s emphasis on forging strategic partnerships has further strengthened its market positioning. Collaborations with leading healthcare institutions and research organizations provide not only a competitive advantage but also cost-efficiency in securing innovation and navigating regulatory barriers. Additionally, Acadia's proactive stance in tapping into underserved markets points toward both growth potential and resilience amid competitive pressures.
Finally, the financial outlook appears reinforced by disciplined capital allocation. Acadia demonstrates improved operating efficiency, reducing cash burn while maintaining sufficient liquidity to fund ongoing R&D initiatives. Investors are likely to interpret these measures as a foundational step for long-term shareholder value creation, mitigating concerns over future dilution risk.
Nuplazid’s strong performance in Q2 demonstrates its potential as a reliable revenue driver for Acadia Pharmaceuticals. The author attributes its continued growth to robust demand in the Parkinson’s disease psychosis space, where competitive pressures remain limited, solidifying its position as a core contributor to the firm's financial stability.
Strategic Product Performance: Opportunities and Risks
However, Daybue’s disappointing performance is a notable challenge, as it fails to meet market expectations for growth in the Rett syndrome space. The underwhelming results suggest weak market uptake or potential execution issues, raising concerns about management’s ability to expand in this high-growth segment.
Operational cost management emerged as a key factor impacting profitability, with spending levels notably higher due to the dual commercialization efforts for Nuplazid and Daybue. While this strategy supports long-term growth ambition, it strains near-term margins and could weigh on investor sentiment.
Finally, the author underscores that the company’s reliance on a narrow portfolio remains a medium-term risk. Acadia’s future growth will depend on diversification efforts or ongoing success from its flagship drugs to mitigate volatility in revenue streams.
Acadia Pharmaceuticals' recent movements suggest a renewed potential for upward momentum, underpinned by core strategic drivers. The company's strengthened focus on its commercial pipeline, with particular emphasis on its flagship drug Nuplazid, showcases promising growth potential in its primary indications. The continued expansion into other therapeutic areas, such as Rett syndrome, provides diversification to the revenue base, which is significant for mitigating risks associated with over-reliance on one product.
Key Catalysts Supporting Positive Momentum
The financial performance, particularly improving quarterly results, reflects operational efficiency and effective resource allocation. This is crucial in building investor confidence, especially in a volatile sector like biotechnology. Additionally, Acadia's forward momentum in exploring partnerships or M&A opportunities suggests strategic positioning to drive both revenue and market footprint growth. If executed effectively, such initiatives could lead to near-term valuation boosts.
The regulatory environment remains a decisive factor, with potential FDA approvals serving as major catalysts for stock movement. However, any delays or issues in this area could pose significant risks. Finally, the company’s balance sheet health, coupled with robust R&D investment, underscores its preparedness for sustained long-term growth, even as it seeks to capitalize on imminent market opportunities.
Acadia Pharmaceuticals is poised for significant growth driven by its flagship products Nuplazid and Daybue within the Central Nervous System (CNS) treatment market. Nuplazid, a key treatment for Parkinson's disease psychosis, continues to exhibit strong sales momentum, bolstered by increasing physician adoption and expanding insurance coverage. This stability in revenue generation positions the drug as an essential contributor to near-term cash flows.
Expanding Opportunities Through Product Innovation
Daybue, recently approved for Rett syndrome, marks a pivotal step in Acadia's diversification strategy within rare CNS disorders. Analysts, including the author, view its market penetration as a transformative growth avenue, with the potential to drive a substantial uptick in the company's top line as the product gains traction post-launch.
Additionally, Acadia's pipeline of innovative CNS-focused therapies underscores the company's long-term growth potential. The emphasis on addressing unmet clinical needs within niche CNS segments strengthens Acadia’s positioning as a key player in this therapeutic domain, while providing a hedge against revenue concentration risks presented by its core products.
Finally, the company’s commitment to operational discipline, reflected in controlled costs and revenue allocation to R&D, enhances its ability to navigate market pressures effectively. This operational efficiency ensures that Acadia can sustain its growth trajectory while maintaining margin stability, creating strong tailwinds for the stock's performance.
The clinical setback of Pimavanserin, Acadia’s flagship drug for expanded indications, serves as a critical blow to investor confidence. This development diminishes the company's near-term growth prospects, given the heavy reliance on the drug as a revenue driver beyond its existing approval for Parkinson’s disease psychosis. The author highlights that the market's negative sentiment is justified in the context of reduced pipeline potential and increased competition.
Key Drivers and Implications for ACAD's Valuation
Acadia’s future hinges significantly on the diversification of its pipeline amidst this setback, as referenced by the author. While there are promising early-stage assets in development, the prolonged timelines and uncertain success rates could delay meaningful contributions to revenues and lead to investor caution in the short to medium term.
The current competitive landscape in neurological and psychiatric therapeutics further compounds pressure on ACAD. Competitors advancing complementary treatments without such clinical hurdles are poised to erode the company’s market share and exacerbate challenges to maintaining growth momentum.
Finally, heightened market volatility and investor aversion to risk amplify the sensitivity of ACAD’s stock to negative news. This underscores a critical need for management to restore confidence through either successful pipeline milestones or strategic partnerships, a factor well-emphasized in the analysis.
Comprehensive Analysis of ACADIA Pharmaceuticals (ACAD) Stock Market Performance
Our multifaceted analysis of ACADIA Pharmaceuticals's stock market is grounded in the company's key news stories, insights from reputable analysts, as well as mathematical and technical evaluations. Taking into account assessments from each of these aspects in real-time helps us address the most crucial questions for investors in the most objective way possible:
- When should I take profit in ACADIA Pharmaceuticals stock?
- When should I record a loss on ACADIA Pharmaceuticals stock?
- What are analysts' forecasts for ACADIA Pharmaceuticals stock?
- What is the future of ACADIA Pharmaceuticals stock?
We forecast ACADIA Pharmaceuticals stock performance using neural networks based on historical data on ACADIA Pharmaceuticals stocks.
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, specializes in the development and commercialization of small molecule drugs designed to meet unmet medical needs in diseases of the central nervous system.
ACADIA Pharmaceuticals Inc. News influencing stock rates

As of now, Panda has combed through 3 news items directly related to ACAD from the last 30 days. Out of these, 2 clearly showcase a bullish trend, while 1 display bearish tendencies, and 0 events are neutral.
The strength of the bullish trend outpaces the bearish sentiments by 2 times, indicating that the news backdrop is positively influencing the company’s stock price in the current outlook.
The news analyzed fell within the period from May 07, 2025, to May 09, 2025.
Acadia Pharma EPS Surpasses Expectations, Revenue Misses Target


Acadia Pharma Set to Report Q4 Earnings: Expecting Solid Growth


Acadia Forecasts Billion-Dollar Breakthrough by 2025


Wall Street Turmoil: ACADIA Pharmaceuticals Shines Amidst Decline


Acadia Pharmaceuticals Joins S&P SmallCap 600 Following Bank Acquisition


Acadia Sells FDA Voucher for $150M Cash Boost


Acadia Secures $610M Deal for Essential Tremor Treatment with Saniona


Acadia Pharma Surpasses Q3 Earnings and Revenue Expectations


Acadia Pharma Earnings: Anticipate Growth Amidst Mixed Analyst Sentiments


Acadia Nets $150M from Sale of FDA Priority Voucher


ACADIA Pharmaceuticals daily forecast for a month
Date | Target | Pes. | Opt. | Vol., % |
---|---|---|---|---|
May 17 | 17.43 | 17.19 | 17.75 | 3.22 |
May 18 | 17.58 | 17.21 | 17.92 | 4.14 |
May 19 | 17.13 | 16.73 | 17.23 | 3.01 |
May 20 | 17.26 | 16.87 | 17.63 | 4.51 |
May 21 | 17.30 | 17.14 | 17.48 | 2.00 |
May 22 | 17.67 | 17.32 | 17.89 | 3.28 |
May 23 | 17.50 | 17.13 | 17.74 | 3.56 |
May 24 | 17.47 | 17.12 | 17.87 | 4.38 |
May 25 | 17.63 | 17.32 | 17.82 | 2.84 |
May 26 | 17.84 | 17.65 | 18.02 | 2.09 |
May 27 | 18.04 | 17.89 | 18.41 | 2.87 |
May 28 | 18.48 | 18.08 | 18.75 | 3.71 |
May 29 | 18.82 | 18.62 | 19.10 | 2.58 |
May 30 | 19.34 | 19.16 | 19.60 | 2.30 |
May 31 | 19.46 | 19.01 | 19.61 | 3.16 |
Jun 01 | 20.00 | 19.67 | 20.38 | 3.60 |
Jun 02 | 20.22 | 20.02 | 20.45 | 2.12 |
Jun 03 | 20.06 | 19.85 | 20.19 | 1.73 |
Jun 04 | 19.61 | 19.34 | 19.88 | 2.80 |
Jun 05 | 19.07 | 18.61 | 19.45 | 4.49 |
Jun 06 | 19.23 | 19.12 | 19.39 | 1.42 |
Jun 07 | 19.49 | 19.12 | 19.80 | 3.55 |
Jun 08 | 19.28 | 19.03 | 19.53 | 2.65 |
Jun 09 | 19.25 | 18.95 | 19.44 | 2.56 |
Jun 10 | 19.75 | 19.61 | 19.90 | 1.45 |
Jun 11 | 20.03 | 19.86 | 20.29 | 2.18 |
Jun 12 | 19.45 | 19.10 | 19.67 | 2.99 |
Jun 13 | 19.62 | 19.35 | 19.76 | 2.10 |
Jun 14 | 19.79 | 19.38 | 20.20 | 4.23 |
Jun 15 | 19.31 | 19.19 | 19.68 | 2.54 |
ACADIA Pharmaceuticals Daily Price Targets
ACADIA Pharmaceuticals Stock Forecast 05-17-2025.
Forecast target price for 05-17-2025: $17.43.
Positive dynamics for ACADIA Pharmaceuticals shares will prevail with possible volatility of 3.124%.
Pessimistic target level: 17.19
Optimistic target level: 17.75
ACADIA Pharmaceuticals Stock Forecast 05-18-2025.
Forecast target price for 05-18-2025: $17.58.
Positive dynamics for ACADIA Pharmaceuticals shares will prevail with possible volatility of 3.973%.
Pessimistic target level: 17.21
Optimistic target level: 17.92
ACADIA Pharmaceuticals Stock Forecast 05-19-2025.
Forecast target price for 05-19-2025: $17.13.
Negative dynamics for ACADIA Pharmaceuticals shares will prevail with possible volatility of 2.922%.
Pessimistic target level: 16.73
Optimistic target level: 17.23
ACADIA Pharmaceuticals Stock Forecast 05-20-2025.
Forecast target price for 05-20-2025: $17.26.
Positive dynamics for ACADIA Pharmaceuticals shares will prevail with possible volatility of 4.317%.
Pessimistic target level: 16.87
Optimistic target level: 17.63
ACADIA Pharmaceuticals Stock Forecast 05-21-2025.
Forecast target price for 05-21-2025: $17.30.
Positive dynamics for ACADIA Pharmaceuticals shares will prevail with possible volatility of 1.960%.
Pessimistic target level: 17.14
Optimistic target level: 17.48
ACADIA Pharmaceuticals Stock Forecast 05-22-2025.
Forecast target price for 05-22-2025: $17.67.
Positive dynamics for ACADIA Pharmaceuticals shares will prevail with possible volatility of 3.171%.
Pessimistic target level: 17.32
Optimistic target level: 17.89
ACAD (ACAD) Monthly Stock Prediction for 2025
Month | Target | Pes. | Opt. | Vol., % |
---|---|---|---|---|
Jun. | 19.61 | 17.85 | 20.73 | 13.91 |
Jul. | 18.14 | 16.75 | 20.21 | 17.10 |
Aug. | 17.92 | 16.93 | 18.84 | 10.13 |
Sep. | 18.70 | 17.13 | 20.47 | 16.31 |
Oct. | 18.31 | 16.85 | 19.99 | 15.67 |
Nov. | 18.09 | 16.62 | 19.91 | 16.49 |
Dec. | 17.36 | 15.90 | 17.96 | 11.45 |
ACADIA Pharmaceuticals forecast for this year
ACADIA Pharmaceuticals Stock Prediction for Jun 2025
An uptrend is forecast for this month with an optimal target price of $19.6113. Pessimistic: $17.85. Optimistic: $20.73
ACADIA Pharmaceuticals Stock Prediction for Jul 2025
An downtrend is forecast for this month with an optimal target price of $18.1404. Pessimistic: $16.75. Optimistic: $20.21
ACADIA Pharmaceuticals Stock Prediction for Aug 2025
An downtrend is forecast for this month with an optimal target price of $17.9227. Pessimistic: $16.93. Optimistic: $18.84
ACADIA Pharmaceuticals Stock Prediction for Sep 2025
An uptrend is forecast for this month with an optimal target price of $18.7024. Pessimistic: $17.13. Optimistic: $20.47
ACADIA Pharmaceuticals Stock Prediction for Oct 2025
An downtrend is forecast for this month with an optimal target price of $18.3096. Pessimistic: $16.85. Optimistic: $19.99
ACADIA Pharmaceuticals Stock Prediction for Nov 2025
An downtrend is forecast for this month with an optimal target price of $18.0899. Pessimistic: $16.62. Optimistic: $19.91
ACADIA Pharmaceuticals Stock Prediction for Dec 2025
An downtrend is forecast for this month with an optimal target price of $17.3573. Pessimistic: $15.90. Optimistic: $17.96
ACADIA Pharmaceuticals (ACAD) Monthly Stock Prediction for 2026
Month | Target | Pes. | Opt. | Vol., % |
---|---|---|---|---|
Jan | 16.60 | 15.16 | 17.70 | 14.35 |
Feb | 17.05 | 16.41 | 18.69 | 12.18 |
Mar | 19.12 | 16.88 | 20.84 | 18.99 |
Apr | 18.29 | 16.18 | 19.11 | 15.36 |
May | 16.42 | 14.92 | 18.10 | 17.56 |
Jun | 16.25 | 15.59 | 16.84 | 7.38 |
Jul | 17.91 | 15.84 | 18.72 | 15.36 |
Aug | 19.79 | 19.14 | 20.47 | 6.53 |
Sep | 18.43 | 16.49 | 19.20 | 14.11 |
Oct | 17.73 | 16.62 | 19.49 | 14.74 |
Nov | 19.06 | 17.58 | 19.86 | 11.52 |
Dec | 19.15 | 17.89 | 21.33 | 16.16 |
ACADIA Pharmaceuticals (ACAD) Monthly Stock Prediction for 2027
Month | Target | Pes. | Opt. | Vol., % |
---|---|---|---|---|
Jan | 18.52 | 17.52 | 20.21 | 13.33 |
Feb | 19.63 | 17.98 | 20.75 | 13.34 |
Mar | 18.42 | 16.57 | 20.58 | 19.47 |
Apr | 17.87 | 16.37 | 19.77 | 17.22 |
May | 17.33 | 16.19 | 18.11 | 10.62 |
Jun | 18.92 | 17.22 | 20.65 | 16.63 |
Jul | 18.32 | 16.12 | 19.09 | 15.55 |
Aug | 20.11 | 18.96 | 22.46 | 15.58 |
Sep | 20.62 | 19.23 | 22.51 | 14.57 |
Oct | 18.40 | 16.99 | 20.05 | 15.28 |
Nov | 18.42 | 17.32 | 20.03 | 13.52 |
Dec | 16.43 | 15.67 | 17.07 | 8.23 |
ACADIA Pharmaceuticals information and performance
3611 VALLEY CENTRE DRIVE, SUITE 300, SAN DIEGO, CA, US
Market capitalization of the ACADIA Pharmaceuticals Inc. is the total market value of all issued shares of a company. It is calculated by the formula multiplying the number of ACAD shares in the company outstanding by the market price of one share.
EBITDA of ACADIA Pharmaceuticals is earnings before interest, income tax and depreciation of assets.
P/E ratio (price to earnings) - shows the ratio between the price of a share and the company's profit
Price/earnings to growth
Dividend Per Share is a financial indicator equal to the ratio of the company's net profit available for distribution to the annual average of ordinary shares.
Dividend yield is a ratio that shows how much a company pays in dividends each year at the stock price.
EPS shows how much of the net profit is accounted for by the common share.
Trailing P/E depends on what has already been done. It uses the current share price and divides it by the total earnings per share for the last 12 months.
Forward P/E uses projections of future earnings instead of final numbers.
Enterprise Value (EV) /Revenue
The EV / EBITDA ratio shows the ratio of the cost (EV) to its profit before tax, interest and amortization (EBITDA).
Number of issued ordinary shares
Number of freely tradable shares
Shares Short Prior Month - the number of shares in short positions in the last month.
FAQ (Frequently Asked Questions about ACADIA Pharmaceuticals Stock)
Should I Buy ACADIA Pharmaceuticals Shares in 2025 year?
Does ACADIA Pharmaceuticals pay dividends?
Which economic sector do ACADIA Pharmaceuticals's shares belong to?
Which other securities belong to the same sector as ACADIA Pharmaceuticals's shares?
Related stocks from Healthcare sector
All forecast data on the site are provided for informational purposes of using neural forecasting tools in the financial market and are not a call to action and, moreover, are not trading signals. When using the forecast data, the investor assumes all financial risks. The pandaforecast.com portal is not responsible for the loss of your money in the stock market as a result of using the information contained on the site.